4-(2,6-二羟基苯甲酰)-3-甲酰基-5-羟基苯甲酸 | 127448-92-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2,6-二羟基苯甲酰)-3-甲酰基-5-羟基苯甲酸
• 中文别名: 2-(4-异硫氰基苯甲基)-1,4,7-三氮杂环壬烷-1,4,7-三乙酸
• 英文名称: TAN-931
• 英文别名: 4-(2,6-Dihydroxybenzoyl)-3-formyl-5-hydroxybenzoic acid
• CAS: 127448-92-4
• 化学式: C₁₅H₁₀O₇
• 分子量: 302.24
• InChiKey: INVAPAXTQZQLGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(2,6-二羟基苯甲酰)-3-甲酰基-5-羟基苯甲酸 生成 4-(3-chloro-2,6-dihydroxybenzoyl)-5-hydroxybenzene-1,3-dicarboxylic acid
  参考文献：
  名称：

  KANAMARU, TSUNEO;HIDA, TSUNEAKI;MUROI, MASAYUKI

  摘要：

  DOI：

文献信息

• Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
  申请人：Wang Changjin

  公开号：US20100087402A1

  公开（公告）日：2010-04-08

  The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.

  本发明涉及治疗依赖雌激素的子宫过度增生性疾病，包括子宫内膜异位症、子宫肌瘤、子宫内膜增生、子宫癌及其相关症状，通过阴道给药至少两种活性药物，所选药物包括芳香化酶抑制剂、抗炎药和子宫选择性雌激素受体拮抗剂。这种联合疗法降低了局部雌激素产生，阻断了局部雌激素作用，并在局部抑制了炎症，导致对依赖雌激素的疾病组织的饥饿，缓解相关症状，延缓疾病进展。阴道给药最大限度地抑制了局部雌激素产生，而不显著影响全身循环雌激素水平。这导致增强的临床疗效和减少的副作用。
• Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
  申请人：Pharmacia Corporation

  公开号：US20040053900A1

  公开（公告）日：2004-03-18

  The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder or osteoporosis in a mammal using a combination of a COX-2 inhibitor and an aromatase inhibitor.

  本发明提供了一种使用COX-2抑制剂和芳香化酶抑制剂的组合物和方法，用于治疗、预防或抑制哺乳动物中的肿瘤、肿瘤相关疾病或骨质疏松症。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND AN AROMATASE INHIBITOR
  申请人：Pharmacia Corporation

  公开号：EP1653940A1

  公开（公告）日：2006-05-10
• BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
  申请人：Nuevolution A/S

  公开号：EP2558577B1

  公开（公告）日：2018-12-12